The botulinum toxin market features more than one brand. Botox (onabotulinumtoxinA), Dysport (abobotulinumtoxinA) and Xeomin (incobotulinumtoxinA) are the three most widely used preparations. Each has a different formulation, dose equivalency, and clinical profile.

Botox (OnabotulinumtoxinA)

Botox, manufactured by Allergan, is the most widely used botulinum toxin brand in the world. It contains a 900 kDa complex protein. Its FDA-approved indications include glabellar lines, crow's feet, forehead lines, chronic migraine, hyperhidrosis, and spasticity.

Stored at 2–8°C, it is recommended to be used within 24 hours after reconstitution. Effects begin within 3–5 days and last an average of 3–4 months.

Dysport (AbobotulinumtoxinA)

Dysport, manufactured by Galderma, has a lower molecular weight formulation. It spreads over a wider area than Botox — an advantage in large muscle regions, though precise dosing is required in smaller muscle groups.

Its dose equivalency ratio compared to Botox is approximately 2.5–3:1; meaning 1 unit of Botox corresponds to approximately 2.5–3 units of Dysport.

Xeomin (IncobotulinumtoxinA)

Xeomin, manufactured by Merz, is a pure botulinum toxin formulation free of complexing proteins. Weighing 150 kDa, it contains no accessory proteins. This characteristic may theoretically reduce the risk of neutralizing antibody formation.

Its ability to be stored at room temperature provides a logistical advantage. Its dose equivalency to Botox is approximately 1:1.

Comparison Summary

Which Brand Should You Choose?

Brand selection should be determined by the physician's experience, the treatment area, and the patient's individual response. If results are insufficient with one brand, switching to another can be tried. All three products are safe and effective, with similar satisfaction rates reported in clinical studies. It is recommended that you determine the most appropriate option together with your physician.

This article is for informational purposes only. Please consult a qualified physician for treatment decisions.